Are there any approved disease-modifying treatments for Parkinson's right now?

Not yet. Every currently approved Parkinson's medication, including levodopa, manages symptoms. Disease-modifying treatments are an active area of research with multiple late-stage trials underway, but none have been approved as of 2026.

Why do disease-modifying trials usually run longer?

Slowing the underlying disease only shows up over time. Researchers need to track participants for at least a year, often longer, to detect a difference between the treatment group and the comparison group. Symptom changes can show up in weeks. Disease changes need years.

Can I be in both kinds of trials at the same time?

Usually no. Most trials require participants not to be enrolled in another interventional study at the same time. You can move from one trial to another after the first ends, and you can usually combine an interventional trial with a separate observational study if both teams agree.

Disease-Modifying vs Symptomatic Parkinson's Trials: What's the Difference?

Researchers and clinicians talk about two different kinds of Parkinson's treatment goals: disease-modifying and symptomatic. Both are important. They are not interchangeable, and the difference shapes which trials might be worth your family's time.

What Symptomatic Treatments Do

A symptomatic treatment manages the symptoms a person experiences. It does not change the underlying disease. The dopamine producing neurons that have been lost are still lost. While the treatment is working, day to day life is better. Levodopa is the most common example. Most currently approved Parkinson's medications and many active trials are symptomatic, focused on reducing OFF time, smoothing wearing off, or improving non motor symptoms like sleep and mood.

What Disease-Modifying Treatments Try to Do

A disease-modifying treatment tries to slow, stop, or reverse the underlying biology of Parkinson's. There is currently no FDA approved disease-modifying treatment. Approaches being tested include GLP-1 receptor agonists like lixisenatide, repurposed drugs like telmisartan and terazosin in the EJS ACT-PD trial, alpha-synuclein antibodies, stem cell derived dopamine neurons, and gene therapies for the small subset of Parkinson's with a known genetic cause.

A Side by Side Look

Goal: Symptomatic feels better now. Disease-modifying changes the path of the disease.
How quickly effects appear: Symptomatic effects can show up within hours or weeks. Disease-modifying effects only appear over many months or years of comparison.
Trial length: Symptomatic trials are often months long. Disease-modifying trials usually run a year or more.
Eligibility: Symptomatic trials often recruit people experiencing the symptom being studied. Disease-modifying trials often recruit people earlier, sometimes within 2 years of diagnosis.

How to Tell Them Apart on a Listing

If the primary outcome is a symptom score (UPDRS motor score change, ON time, OFF time, sleep quality), the trial is usually symptomatic.
If the primary outcome is rate of disease progression or change in a disease biomarker over a year or more, it is usually disease-modifying.
If eligibility specifies "within 2 years of diagnosis" and the trial is long, that is often a disease-modifying study.
If the intervention is a known symptom medication like a levodopa formulation, it is almost always symptomatic.

Why This Matters for Your Family

Symptomatic trials target what is hard right now. Disease-modifying trials are where research is moving the field forward, and they typically ask for a longer commitment. Most families consider both at different times.

Browse trials filtered for disease-modifying research or symptomatic studies using keyword search.

Frequently Asked Questions

Are there any approved disease-modifying treatments for Parkinson's right now?: Not yet. Every currently approved Parkinson's medication, including levodopa, manages symptoms. Disease-modifying treatments are an active area of research with multiple late-stage trials underway, but none have been approved as of 2026.
Why do disease-modifying trials usually run longer?: Slowing the underlying disease only shows up over time. Researchers need to track participants for at least a year, often longer, to detect a difference between the treatment group and the comparison group. Symptom changes can show up in weeks. Disease changes need years.
Can I be in both kinds of trials at the same time?: Usually no. Most trials require participants not to be enrolled in another interventional study at the same time. You can move from one trial to another after the first ends, and you can usually combine an interventional trial with a separate observational study if both teams agree.